Cancer's relationship with cellular oxidative stress presents a critical vulnerability that could revolutionize treatment approaches. While healthy cells maintain balanced oxidative environments, malignant cells operate in a precarious state of elevated reactive oxygen species that simultaneously fuels their growth and creates their downfall. Malignant cells generate excessive ROS through hyperactive metabolism, damaged mitochondria, and oncogene activation. This moderate oxidative stress drives cancer progression by damaging DNA, destabilizing genomes, and activating survival pathways while building resistance to standard therapies. Yet this same oxidative burden creates cancer's Achilles heel—push ROS levels slightly higher, and the cellular machinery collapses through programmed death pathways including apoptosis, autophagy, and ferroptosis. This narrow therapeutic window offers unprecedented targeting opportunities. Unlike normal cells with robust antioxidant reserves, cancer cells already operate near their oxidative breaking point. Therapeutic strategies exploiting this vulnerability include overwhelming cancer cells with additional ROS, dismantling their antioxidant defenses, or blocking the signaling networks they use to survive oxidative stress. The approach represents a fundamental shift from attacking cancer's strengths to exploiting its metabolic dependencies. Early research suggests combining oxidative therapies with traditional treatments could overcome drug resistance patterns. However, the challenge lies in achieving cancer-selective toxicity without harming healthy tissues, requiring precise understanding of each tumor's unique redox signature to guide personalized treatment protocols.